Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Intensity Therapeutics Inc’s stock clocked out at $0.29, down -1.27% from its previous closing price of $0.3. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 3.26 million shares were traded. INTS stock price reached its highest trading level at $0.3194 during the session, while it also had its lowest trading level at $0.2911.
Ratios:
To gain a deeper understanding of INTS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INTS now has a Market Capitalization of 13867904 and an Enterprise Value of 11776912.
Stock Price History:
The Beta on a monthly basis for INTS is 3.79, which has changed by -0.9292566 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, INTS has reached a high of $4.40, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is -8.42%, while the 200-Day Moving Average is calculated to be -81.25%.
Shares Statistics:
It appears that INTS traded 3.84M shares on average per day over the past three months and 4737410 shares per day over the past ten days. A total of 26.17M shares are outstanding, with a floating share count of 25.35M. Insiders hold about 46.12% of the company’s shares, while institutions hold 4.20% stake in the company. Shares short for INTS as of 1753920000 were 945059 with a Short Ratio of 0.25, compared to 1751241600 on 412820. Therefore, it implies a Short% of Shares Outstanding of 945059 and a Short% of Float of 2.32.
Earnings Estimates
The current rating of Intensity Therapeutics Inc (INTS) is the result of assessments by 1 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.07 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.38 and -$0.38 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.37, with 2.0 analysts recommending between -$0.24 and -$0.5.
